AnaptysBio (NASDAQ:ANAB) Insider Sells $182,513.94 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) insider Paul Lizzul sold 4,219 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $43.26, for a total value of $182,513.94. Following the completion of the transaction, the insider directly owned 33,303 shares of the company’s stock, valued at approximately $1,440,687.78. The trade was a 11.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

AnaptysBio Price Performance

Shares of ANAB stock opened at $43.80 on Friday. The stock’s 50-day moving average is $42.46 and its 200 day moving average is $31.30. AnaptysBio, Inc. has a 1-year low of $12.21 and a 1-year high of $52.47. The company has a market cap of $1.21 billion, a P/E ratio of -15.53 and a beta of 0.32.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, beating the consensus estimate of ($1.06) by $1.58. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. The business had revenue of $76.32 million during the quarter, compared to analyst estimates of $15.83 million. On average, analysts anticipate that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio declared that its board has approved a stock repurchase program on Friday, November 21st that permits the company to buyback $100.00 million in shares. This buyback authorization permits the biotechnology company to reacquire up to 9.6% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

More AnaptysBio News

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Anaptys filed a partial motion to dismiss Tesaro (a GSK subsidiary)’s anticipatory breach claim in Delaware Chancery Court, which, if sustained, could reduce near‑term royalty exposure tied to Jemperli sales and lower legal risk. Reuters: AnaptysBio seeks partial dismissal GlobeNewswire: Motion to dismiss filing
• Positive Sentiment: Recent fundamentals and capital actions remain supportive: Anaptys reported an earnings and revenue beat in November and its board authorized up to $100M in share repurchases, which can support the share price over time by signaling management confidence and reducing outstanding float. MarketBeat ANAB coverage
• Neutral Sentiment: Upcoming event: CEO Daniel Faga will present at the J.P. Morgan Healthcare Conference (Jan. 13), which could catalyze new corporate updates or guidance but is unlikely to move the stock absent specific news. GlobeNewswire: JPM presentation
• Neutral Sentiment: Institutional positioning: Several funds have added or initiated positions recently, which can provide longer‑term demand but also increases the potential for large block trades to move the stock. MarketBeat ownership data
• Negative Sentiment: Insider selling: Multiple insiders (including the CEO and CFO) disclosed sizable sales on Jan. 5–7 that materially reduced their holdings; public Form 4 filings and media reports of these sales are likely contributing to today’s downward pressure as some investors view clustered insider sales negatively. InsiderTrades: insider selling alerts

Institutional Trading of AnaptysBio

Several large investors have recently added to or reduced their stakes in ANAB. Larson Financial Group LLC increased its holdings in shares of AnaptysBio by 54.6% in the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 473 shares during the period. Bessemer Group Inc. boosted its position in AnaptysBio by 950.0% in the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 1,292 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in AnaptysBio by 175.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,377 shares during the last quarter. Osaic Holdings Inc. increased its holdings in AnaptysBio by 11,630.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after buying an additional 2,326 shares during the period. Finally, Covestor Ltd raised its position in AnaptysBio by 131,540.0% during the 3rd quarter. Covestor Ltd now owns 6,582 shares of the biotechnology company’s stock worth $201,000 after buying an additional 6,577 shares during the last quarter.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Stifel Nicolaus reduced their price target on AnaptysBio from $80.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday, December 11th. Guggenheim restated a “buy” rating on shares of AnaptysBio in a research note on Thursday, December 18th. Truist Financial increased their price target on AnaptysBio from $20.00 to $36.00 and gave the company a “hold” rating in a research note on Monday, November 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of AnaptysBio in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of AnaptysBio from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 16th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $60.40.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.